Infant Bacterial Therapeutics AB
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00CB3BRH4
IBT B
Infant Bacterial Therapeutics AB
GICS: -
·
Sector: Health Care
·
Sub-Sector: Health Care
NAME
Infant Bacterial Therapeutics AB
ISIN
SE0008015259
TICKER
IBT B
MIC
XSTO
REUTERS
IBTB.ST
BLOOMBERG
IBTB SS
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
Four Short sale positions >= 0.50% are currently registered as reportable-relevant
| Date | Position Holder | Position | # | Action |
|---|---|---|---|---|
| 25.03.2019 | SQUAREPOINT OPS LLC | 0,50% | 2 | |
| 16.02.2018 | GUEVOURA FUND | 0,50% | 2 | |
| 30.01.2018 | Susquehanna International Holding LLC | 0,50% | 1 | |
| 20.05.2016 | Susquehanna International Holdings LLC | 1,38% | 3 |
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
| Date | Position Holder | Position | # | Action |
|---|---|---|---|---|
| 25.03.2019 | SQUAREPOINT OPS LLC | 0,50% | 2 | |
| 16.02.2018 | GUEVOURA FUND | 0,50% | 2 | |
| 30.01.2018 | Susquehanna International Holding LLC | 0,50% | 1 | |
| 20.05.2016 | Susquehanna International Holdings LLC | 1,38% | 3 |
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.
